Pharmacologic and surgical interventions to improve functional capacity in heart failure

Heart Failure Clinics

Volumn 11, Issue 1, 2015, Pages 117-124

  Abbate, Antonio ^a   Van Tassell, Benjamin W ^a   Canada, Justin M ^a   Dixon, Dave L ^a   Arena, Ross A ^b   Biondi Zoccai, Giuseppe ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Device; Drugs; Functional capacity; Heart failure; Surgery; Treatments

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; IVABRADINE; LOOP DIURETIC AGENT; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; VASODILATOR AGENT; CARDIOTONIC AGENT;

CARDIAC RESYNCHRONIZATION THERAPY; COMORBIDITY; DEATH; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FILLING; HEART RATE; HOSPITALIZATION; HUMAN; MORTALITY; PROGNOSIS; REVIEW; VENTRICULAR ASSIST DEVICE; DAILY LIFE ACTIVITY; EXERCISE TEST; HEART SURGERY; HEART VENTRICLE FUNCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ACTIVITIES OF DAILY LIVING; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; EXERCISE TEST; HEART FAILURE; HUMANS; VENTRICULAR FUNCTION;

EID: 84922688052     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.08.005     Document Type: Review

References (46)

1. Braunwald E. Heart failure. JACC Heart Fail 2013, 1(1):1-20.
2. Writing Committee Members, Yancy C.W., Jessup M., American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 128(16):e240-e327.
3. Hung J., Kelly D.T., Hutton B.F., et al. Influence of heart rate and atrial transport on left ventricular volume and function: relation to hemodynamic changes produced by supraventricular arrhythmia. Am J Cardiol 1981, 48(4):632-638.
4. Orn S., Dickstein K. How do heart failure patients die?. Eur Heart J 2002, 4(Suppl):D59-D65.
5. Huikuri H.V., Castellanos A., Myerburg R.J. Sudden death due to cardiac arrhythmias. NEngl J Med 2001, 345:1433-1442.
6. Cahalin L.P., Chase P., Arena R., et al. Ameta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev 2013, 18(1):79-94.
7. Moss A.J., Zareba W., Hall W.J., Multicenter Automatic Defibrillator Implantation Trial II Investigators, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346(12):877-883.
8. Creager M.A., Massie B.M., Faxon D.P., et al. Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. JAm Coll Cardiol 1985, 6(1):163-173.
9. Lang R.M., Elkayam U., Yellen L.G., et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. JAm Coll Cardiol 1997, 30(4):983-991.
10. Ziesche S., Cobb F.R., Cohn J.N., et al. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87(6 Suppl):VI56-VI64.
11. Magorien R.D., Leier C.V., Kolibash A.J., et al. Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure. Circulation 1984, 70(5):884-890.
12. Dunselman P.H., Kuntze C.E., van Bruggen A., et al. Efficacy of felodipine in congestive heart failure. Eur Heart J 1989, 10(4):354-364.
13. Walsh J.T., Andrews R., Curtis S., et al. Effects of amlodipine in patients with chronic heart failure. Am Heart J 1997, 134(5 Pt 1):872-878.
14. Udelson J.E., DeAbate C.A., Berk M., et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 2000, 139(3):503-510.
15. Metra M., Nardi M., Giubbini R., et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. JAm Coll Cardiol 1994, 24(7):1678-1687.
16. Metra M., Giubbini R., Nodari S., et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000, 102(5):546-551.
17. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation 1995, 92(2):212-218.
18. Conraads V.M., Metra M., Kamp O., et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012, 14(2):219-225.
19. Cicoira M., Zanolla L., Rossi A., et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. JAm Coll Cardiol 2002, 40(2):304-310.
20. Eshaghian S., Horwich T.B., Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006, 97(12):1759-1764.
21. Gupta S., Waywell C., Gandhi N., et al. The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. Eur J Heart Fail 2010, 12(7):746-752.
22. Agostoni P.G., Marenzi G.C., Pepi M., et al. Isolated ultrafiltration in moderate congestive heart failure. JAm Coll Cardiol 1993, 21(2):424-431.
23. Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. NEngl J Med 1997, 336(8):525-533.
24. Sullivan M., Atwood J.E., Myers J., et al. Increased exercise capacity after digoxin administration in patients with heart failure. JAm Coll Cardiol 1989, 13(5):1138-1143.
25. Fleg J.L., Rothfeld B., Gottlieb S.H. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. JAm Coll Cardiol 1991, 17(3):743-751.
26. Speranza L., Franceschelli S., Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules 2012, 17(5):4924-4935.
27. Sarullo F.M., Fazio G., Puccio D., et al. Impact of 'off-label' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. JCardiovasc Pharmacol Ther 2010, 15(4):349-355.
28. Kosmala W., Holland D.J., Rojek A., et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JAm Coll Cardiol 2013, 62(15):1330-1338.
29. Fox K., Ford I., Steg P.G., BEAUTIFUL investigators, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372(9641):817-821.
30. Swedberg K., Komajda M., Böhm M., SHIFT Investigators, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376(9744):875-885. [Erratum appears in Lancet 2010;376(9757):1988]. 10.1016/S0140-6736(10)61198-1.
31. Uretsky B.F., Jessup M., Konstam M.A., et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990, 82(3):774-780.
32. Bocchi E.A., Guimarães G., Mocelin A., et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002, 106(9):1097-1103.
33. Guazzi M., Tumminello G., Di Marco F., et al. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. JAm Coll Cardiol 2004, 44(12):2339-2348.
34. Guazzi M., Myers J., Peberdy M.A., et al. Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. Int J Cardiol 2010, 144(3):410-412.
35. Sanada S., Asanuma H., Koretsune Y., et al. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Hypertens Res 2007, 30(10):913-919.
36. Redfield M.M., Chen H.H., Borlaug B.A., RELAX Trial, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309(12):1268-1277.
37. Prinzen F.W., Vernooy K., Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation 2013, 128(22):2407-2418.
38. Shah K.B., Tang D.G., Cooke R.H., et al. Implantable mechanical circulatory support: demystifying patients with ventricular assist devices and artificial hearts. Clin Cardiol 2011, 34(3):147-152.
39. Jung M.H., Hansen P.B., Sander K., et al. Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. Eur J Heart Fail 2014, [EPub ahead of print]. Accessed September 22, 2014.
40. Noor M.R., Bowles C., Banner N.R. Relationship between pump speed and exercise capacity during HeartMate II left ventricular assist device support: influence of residual left ventricular function. Eur J Heart Fail 2012, 14:613-620.
41. Kohli H.S., Canada J., Arena R., et al. Exercise blood pressure response during assisted circulatory support: comparison of the total artificial heart with a left ventricular assist device during rehabilitation. JHeart Lung Transplant 2011, 30:1207-1213.
42. Brubaker P.H., Kitzman D.W. Prevalence and management of chronotropic incompetence in heart failure. Curr Cardiol Rep 2007, 9(3):229-235.
43. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006, 114(5):e84-e231. [review], [Erratum appears in Circulation 2007;115(15):e409; Circulation 2010;121(23):e443].
44. Guazzi M., Myers J., Vicenzi M., et al. Cardiopulmonary exercise testing characteristics in heart failure patients with and without concomitant chronic obstructive pulmonary disease. Am Heart J 2010, 160(5):900-905.
45. Okonko D.O., Mandal A.K., Missouris C.G., et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. JAm Coll Cardiol 2011, 58(12):1241-1251.
46. Nicoletti I., Cicoira M., Zanolla L., et al. Skeletal muscle abnormalities in chronic heart failure patients: relation to exercise capacity and therapeutic implications. Congest Heart Fail 2003, 9(3):148-154.